Anaplastic thyroid cancer (ATC) is an infrequent thyroid tumor that usually occurs in elderly
patients. There is often a history of previous differentiated thyroid cancer suggesting a …

Aims Anaplastic thyroid cancer (ATC) is a rare but aggressive form of thyroid cancer with a
median survival of 4 months. Recent advances in molecular profiling have shown that up to …

Major advancements took place in the characterization and management of ATC in recent
years, especially in patients with a BRAF V600E mutation. Still, no curative treatment is …

Objective The treatment of anaplastic thyroid cancer (ATC) has continued to rapidly evolve
over time. Increased utilization of novel, personalized therapies based upon the tumour's …

Anaplastic thyroid cancer (ATC) is undoubtedly the thyroid cancer histotype with the poorest
prognosis. The conventional treatment includes surgery, radiotherapy, and conventional …

Background: Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis, despite
systemic cytotoxic chemotherapy. The objective of this study was to investigate the efficacy …

Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib
(MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a …

Objectives Anaplastic thyroid carcinoma (ATC) has a poor survival. The combination of
Dabrafenib plus Trametinib (DT) had a significant impact in survival of BRAF p. V600E …

Thyroid cancer incidence is increasing at an alarming rate, almost tripling every decade. In
2017, it was the fifth most common cancer in women. Although the majority of thyroid tumors …

Anaplastic thyroid carcinoma (ATC) is a rare, but devastating disease. Despite multimodal
approaches combining surgery, chemotherapy and radiation therapy, ATC is associated …